|Slideshows|March 20, 2020

Baby-led weaning: Best practices

Author(s)Megan H Pesch, MD, MS, Sarah P Shubeck, MD, MS, CLC, Heather Burrows, MD, PhD

Baby-led weaning (BLW) is an alternate way to introduce infants to new foods at a developmentally appropriate age. Following some best practices can help ensure that BLW is a rewarding experience for parent and child.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe

Related Content

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata

ByMorgan Ebert, Executive Editor

September 15th 2026

Teen sports supplements: What to recommend, use with caution, and avoid

ByColleen Sloan, PA-C, RDN

September 14th 2026

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves leniolisib for children aged 4 to 11 with APDS

ByBenjamin P. Saylor

September 11th 2026

Latest CME

Video

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Baby-led weaning: Best practices

Related Content

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata

Teen sports supplements: What to recommend, use with caution, and avoid

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves leniolisib for children aged 4 to 11 with APDS

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

Teen sports supplements: What to recommend, use with caution, and avoid

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

How Breast Milk Shapes Gut Microbiome Signaling and Immunity